Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels
Launched by UNIVERSIDAD DE GUANAJUATO · Oct 29, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a treatment called low-intensity transcranial magnetic stimulation (TMS) for people with Major Depressive Disorder (MDD). TMS uses gentle magnetic fields to stimulate specific parts of the brain, which may help improve mood and reduce symptoms of depression. The trial will also look at changes in certain substances in the blood related to mood and brain health, specifically 5-hydroxyindoleacetic acid (5-HIAA) and brain-derived neurotrophic factor (BDNF). Researchers will compare the effects of low-intensity TMS to a sham treatment (a placebo) to see if it truly helps.
To be eligible for the trial, participants should be between 18 and 60 years old, have a diagnosis of MDD from a psychiatrist, and be currently receiving treatment for their condition. They should not have a history of certain medical conditions, like epilepsy or schizophrenia, and must not have metal implants or devices that could interfere with the treatment. Participants will undergo a health assessment, provide blood samples before and after the treatment, and receive TMS for four days. They will be monitored daily for any changes in their depressive symptoms and overall health. This study aims to ensure the safety of TMS and evaluate its effectiveness in helping those with depression.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and 60 years.
- • Both sexes.
- • Those who have a diagnosis of MDD previously made by the treating psychiatrist (considering time since diagnosis and recurrence of episodes).
- • Those who continue with their respective treatment and attend follow-up consultations at the health facility.
- • Those who do not have a history of epilepsy, schizophrenia, neurosurgeries.
- • Those who do not have metal plates anywhere in the skull, neck, chest and shoulder.
- • Those who do not use pacemakers.
- • Those who do not take hormone substitutes.
- • Those who agree to participate in the research.
- Exclusion Criteria:
- • Those who are pregnant.
About Universidad De Guanajuato
The Universidad de Guanajuato is a prestigious academic institution in Mexico, recognized for its commitment to advancing research and education in the health sciences. With a strong emphasis on innovation and interdisciplinary collaboration, the university actively engages in clinical trials aimed at improving healthcare outcomes and addressing pressing medical challenges. The institution is equipped with state-of-the-art facilities and a dedicated team of experienced researchers and clinicians, fostering an environment that promotes ethical standards and rigorous scientific inquiry. Through its clinical trial initiatives, Universidad de Guanajuato aims to contribute valuable insights to the global medical community while enhancing the health and well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
León, Guanajuato, Mexico
Patients applied
Trial Officials
Ma. Eugenia Garay Sevilla, PhD in medical sciences
Study Director
Universidad de Guanajuato
José M De la Roca Chiapas, PhD in medical sciences
Study Director
Universidad de Guanajuato
Blanca O Murillo Ortíz, PhD in medical sciences
Study Director
Universidad de Guanajuato
Angélica Hernández Rayas, Physics PhD
Study Chair
Universidad de Guanajuato
Olga E Escobar Florez, Master of Medical Sciences
Principal Investigator
Universidad de Guanajuato
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported